Senti Biosciences
Team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $37.6m | SPAC Private Placement | |
| Total Funding | 000k | ||
NEA(exited)
Pear Ventures(exited)
Menlo Ventures(exited)
Lux Capital(exited)
Amgen Ventures(exited)
Allen & Company(exited)
Omega Funds(exited)
Nest.Bio Labs(exited)
8VC(exited)
Lifeforce Capital(exited)
Leaps by Bayer(exited)
Matrix Partners China(exited)
Mirae Asset Capital(exited)
Ridgeback Capital(exited)
Intel Capital(exited)
Alexandria Venture Investments(exited)
Gaingels(exited)
KB Investment(exited)
LifeSci Venture Partners(exited)
Noveus Capital(exited)
SmileGate Investment(exited)
Intel Corporation(exited)
Morgan Stanley(exited)
Invus(exited)
T. Rowe Price(exited)
ARK Invest(exited)
Flucas Ventures(exited)
Green Sands Equity(exited)
Goodman Capital(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 481 % | 87 % | (54 %) | - | - | 150 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5703 %) | (1633 %) | (1648 %) | (1999 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5041 %) | (2415 %) | (1358 %) | (3592 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4050 % | 958 % | 795 % | 1625 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.